Pyrotinib
- Generic Name
- Pyrotinib
- Drug Type
- Small Molecule
- Chemical Formula
- C32H31ClN6O3
- CAS Number
- 1269662-73-8
- Unique Ingredient Identifier
- CJN36EQM0H
- Background
Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).
A Drug-drug Interaction Trial of Loperamide Pharmacokinetics Effect on Pyrotinib Maleate
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04315116
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer
Phase 2
Active, not recruiting
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT04293276
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
Phase 2
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 280
- Registration Number
- NCT04290793
Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 27
- Registration Number
- NCT04255056
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 316
- Registration Number
- NCT04254263
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.
Phase 2
- Conditions
- Breast CancerHER2-positive Breast CancerER-positive Breast Cancer
- Interventions
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT04236310
A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer
Phase 1
- Conditions
- HER-2 Positive Colorectal Cancer
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Qingdao Zhixin Health Technology Co., Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT04227041
- Locations
- 🇨🇳
Qingdao University Hospital, Qingdao, Shandong, China
The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor
Phase 2
- Conditions
- HER-2 Protein OverexpressionSolid TumorHER-2 Gene AmplificationHER2 Gene Mutation
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Tianjin Medical University Second Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04179656
- Locations
- 🇨🇳
Tianjin Medical University Second Hospital, Tianjin, Tianjin, China
Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- HER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- xuexin he
- Target Recruit Count
- 60
- Registration Number
- NCT04158856
Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer
Phase 1
- Conditions
- HER2 PositiveCombination ChemotherapyBreast Cancer
- Interventions
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04152057
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Chengdu, Sichuan, China, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath